Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination

1. Generex & Epivax have identified SARS-COV-2 amino acid peptides for epitope evaluation

2. Synthesize 2019-nCoV epitope peptides for screening (standard peptide chemistry – 11 - 15 amino acids)

3. Screen common HLA-DR alleles in vitro vs SARS-COV-2 sequences

4. Test chemical linkers with for best fit for Ii-Key (LRMK) hybrid vaccine – optimize for immunogenicity

5. Select Ii-Key Hybrid/2019-nCoV peptides for vaccine evaluation

6. Collect blood samples & isolate PBMCs from 2019-nCoV infected & recovered individuals

7. Test Ii-Key/ SARS-COV-2 hybrid peptide vaccines vs. PBMcs

8. Conduct Elispot analysis to test for IFN-γ expression indicating CD-4 T-cell activation

9. Select active Ii-Key/ SARS-COV-2 hybrid peptide vaccines for human clinical testing

10. Conduct Clinical Trial with Lead Ii-Key/SARS-COV-2 Peptides • Evaluate safety & immunogenicity (DTH Assay)

11. Select peptides for Multi-valent Ii-Key/ SARS-COV-2 Peptide Vaccine

12. Commercial Manufacturing & Distribution in 5 to 9 months